【作者】 范蓉；

【导师】 谢小薰；

【作者基本信息】 广西医科大学 ， 组织学与胚胎学， 2004， 硕士

【摘要】 目的：探讨三种癌-睾丸抗原用于脑膜瘤免疫治疗的可能性。 方法：采用逆转录-聚合酶链反应(RT-PCR)技术，检测41例人脑膜瘤组织及29例正常组织中三种癌-睾丸抗原(SCP-1、NY-SAR-35和OY-TES-1)的表达情况，并结合癌-睾丸抗原的表达与临床参数进行统计学分析。 结果：SCP-1在所检测的脑膜瘤和正常组织均不表达：NY-SAR-35在正常组织和脑膜瘤组织中的表达频率分别为13.79％(4／29)和36.59％(15／41)，两者比较有显著性差异(p＜0.05)。在14种不同器官的正常组织中，3种表达NY－SAR－35。OY-TES－1在正常组织和脑膜瘤组织中的表达频率分别为68.97％(20／29)和39.02％(16／41)，两者比较有显著性差异(D＜0.05)。在14种不同器官的组织中，12种表达OY-TES-1。NY-SAR-35和OY-TES-1的表达频率分别与脑膜瘤病人的年龄、性别、肿瘤大小、组织类型和临床病理分级进行比较，均无统计学意义(p＞0.05)。 结论：NY-SAR-35在脑膜瘤组织中有较高表达频率，提示它有可能成为脑膜瘤免疫治疗的靶抗原：考虑剑OY-TES-1在正常组织中广泛表达，它是否为真正的痛-睾丸抗原尚需进一步研究。更多还原

【Abstract】 OBJECTIVE: The purpose of this study was to determine the potential of three cancer testis antigens (CTA) as vaccines for human meningioma.METHODS: Forty one specimens of human meningioma and twenty nine specimens of human normal tissues were analyzed for the expression of three CTA genes (SCP-1, NY-SAR-35 and OY-TES-1) by Reverse Transcriptase Chain Reaction (RT-PCR). Correlation between the expression of CTA genes and clinical data was evaluated.RESULTS: All of meningiomas and normal tissues were negative for SCP-1. The expressive frequency of NY-SAR-35 in normal and meningioma tissues was 13.79% (4/29) and 36.59% (15/41), respectively. There was significant difference for the expressive frequency of NY-SAR-35 in both normal and meningioma tissues (p<0. 05). Of 14 specimens of normal tissues from different organs, 3 expressed NY-SAR-35. As to OY-TES-1, the expressive frequency in normal and meningioma tissues was 68.97% (20/29) and 39.02% (16/41), respectively. Significant difference for the expressive frequency of OY-TES-1 in both normal and meningioma tissues has been showed (p<0. 05). Of 14 specimens of normal tissues from different organs, 12 were positive in OY-TES-1. There was no statistic significance for the expression of NY-SAR-35 and OY-TES-1 correlated with patients’ age, sex, histological subtype and clinical pathological grade of meningioma (p>0. 05).CONCLUSION: With higher expressive frequency in meningioma tissues, NY-SAR-35 might be a potential promising target for immunotherapy of meningioma. The fact of broad expression of OY-TES-1 in seriesof normal tissues has been considered, and whether OY-TES-1 was a true cancer testis antigen or not has to be further determined.更多还原